DE69433971D1 - Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis - Google Patents

Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis

Info

Publication number
DE69433971D1
DE69433971D1 DE69433971T DE69433971T DE69433971D1 DE 69433971 D1 DE69433971 D1 DE 69433971D1 DE 69433971 T DE69433971 T DE 69433971T DE 69433971 T DE69433971 T DE 69433971T DE 69433971 D1 DE69433971 D1 DE 69433971D1
Authority
DE
Germany
Prior art keywords
immunodominant
epitopes
hepatitis
virus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69433971T
Other languages
English (en)
Other versions
DE69433971T2 (de
Inventor
Geert Leroux-Roels
Robert Deleys
Geert Maertens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8214764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69433971(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Application granted granted Critical
Publication of DE69433971D1 publication Critical patent/DE69433971D1/de
Publication of DE69433971T2 publication Critical patent/DE69433971T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69433971T 1993-11-04 1994-10-28 Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis Expired - Fee Related DE69433971T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93402718 1993-11-04
EP93402718 1993-11-04

Publications (2)

Publication Number Publication Date
DE69433971D1 true DE69433971D1 (de) 2004-09-30
DE69433971T2 DE69433971T2 (de) 2005-09-08

Family

ID=8214764

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69432475T Revoked DE69432475T2 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
DE69433971T Expired - Fee Related DE69433971T2 (de) 1993-11-04 1994-10-28 Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
DE69434295T Revoked DE69434295T2 (de) 1993-11-04 1994-10-28 Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69432475T Revoked DE69432475T2 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69434295T Revoked DE69434295T2 (de) 1993-11-04 1994-10-28 Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis

Country Status (11)

Country Link
US (4) US6555114B1 (de)
EP (4) EP0992581B2 (de)
JP (2) JPH09504534A (de)
AT (3) ATE290592T1 (de)
AU (1) AU698878B2 (de)
CA (1) CA2175692A1 (de)
DE (3) DE69432475T2 (de)
DK (2) DK0725824T3 (de)
ES (2) ES2197170T3 (de)
PT (2) PT725824E (de)
WO (1) WO1995012677A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510240A (ja) 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
ATE290592T1 (de) * 1993-11-04 2005-03-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU697171B2 (en) * 1994-04-08 1998-10-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure
JP2001522599A (ja) * 1997-11-06 2001-11-20 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断用及びワクチン用、ｃ型肝炎ウイルスエンベロープタンパク質由来マルチマーペプチド
WO1999054735A1 (en) 1998-04-17 1999-10-28 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents
WO1999058561A1 (fr) * 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Mimotopes du virus de l'hepatite c
EP1084253A1 (de) * 1998-06-12 2001-03-21 Aventis Pasteur Mimotope des hiv virus
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
ATE357526T1 (de) 1998-08-21 2007-04-15 Us Gov Health & Human Serv Modifizierte hcv peptid-impfstoffe
DE19908423A1 (de) * 1999-02-26 2000-08-31 Deutsches Krebsforsch An der Entwicklung des ZNS beteiligtes Protein (TP)
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU2000273396A1 (en) * 2000-09-01 2002-03-22 Epimmune, Inc. Hla binding peptides and their uses
GB0026094D0 (en) * 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
US8129349B2 (en) * 2000-10-27 2012-03-06 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1381671A2 (de) 2001-04-24 2004-01-21 Innogenetics N.V. Konstrukte und methoden zur expression von rekombinanten hcv huellproteinen
FR2825093B1 (fr) * 2001-05-28 2003-07-18 Bio Merieux Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations
FR2825363A1 (fr) * 2001-05-31 2002-12-06 Bio Merieux Polypeptides reagissant avec les anticorps de patients infectes par vhc et utilisations
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
JP2003064096A (ja) * 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
CA2468690A1 (en) * 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US7201904B2 (en) 2002-05-16 2007-04-10 The General Hospital Corporation Epitopes of hepatitis C virus
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
JP2005532064A (ja) * 2002-07-02 2005-10-27 カイロン コーポレイション 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質
CA2504711A1 (en) * 2002-11-08 2004-05-21 Innogenetics N.V. Hcv vaccine compositions comprising e1 and ns3 peptides
US20060269562A1 (en) * 2003-01-07 2006-11-30 Christine Bain Polypeptides f' of the hepatitis c virus, t epitopeo, and the diagnostic and therapeutic applications thereof
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
JP2008505636A (ja) * 2004-07-03 2008-02-28 モガム バイオテクノロジー リサーチ インスティチュート Ｈｃｖに有効なｃｔｌ反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途
CU23470A1 (es) * 2004-08-11 2009-12-17 Ct Ingenieria Genetica Biotech Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c
US7381705B2 (en) * 2004-09-29 2008-06-03 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitis C virus
WO2006044923A2 (en) * 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
EP1888751A2 (de) * 2005-05-25 2008-02-20 Tripep Ab Nichtstrukturelles ns3/4a-fusionsgen des hepatitis-c-virus
US20090238822A1 (en) * 2005-10-13 2009-09-24 Virexx Medical Corp. Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response
US20080031982A1 (en) * 2006-06-20 2008-02-07 Metaproteomics, Llc Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
BRPI0713978A2 (pt) * 2006-06-28 2012-11-27 Statens Seruminstitut expansão do repertório de células t para incluir epìtopos subdominantes através da vacinação com antìgeneos leberados como fragmentos de protéinas ou coquetéis de peptìdeo
EP2185195A2 (de) * 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
ES2303496B1 (es) * 2008-02-21 2009-07-07 Fundacion Para El Estudio De Las Hepatitis Virales Metodo analitico perfeccionado para la deteccion de hepatitis c oculta, aplicaciones del mismo y su correspondiente kit de diagnostico.
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
EP2411049B1 (de) * 2009-03-27 2020-01-15 Academia Sinica Verfahren und zusammensetzungen zur immunisierung gegen viren
CN102378914B (zh) * 2009-03-30 2014-12-10 生物梅里埃公司 用于hcv检测的固体支持物
US20130183376A1 (en) * 2010-09-08 2013-07-18 Saitama Medical University Hepatitis c virus liposome vaccine
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
EP2646459B1 (de) 2010-12-02 2020-01-08 Bionor Immuno AS Peptidgerüstentwurf
CN103347892B (zh) 2011-01-06 2016-11-02 比奥诺尔免疫有限公司 单体和多聚体免疫原性肽
EP2859011B1 (de) 2012-06-06 2019-12-11 Bionor Immuno AS Peptide aus viralen proteinen zur verwendung als immunogene oder nachweisreagenzien
US9925259B2 (en) 2013-02-19 2018-03-27 National University Corporation Kobe University Immunogenic polypeptide surface layer-expressing bifidobacterium
EP3916103A1 (de) * 2013-03-14 2021-12-01 Abbott Laboratories Monoklonale antikörper gegen hcv-core lipid-bindender domäne
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
EP2968526A4 (de) 2013-03-14 2016-11-09 Abbott Lab Hcv-antigen-antikörper-kombinationstest sowie verfahren und zusammensetzungen zur verwendung darin
CN105555310B (zh) * 2013-07-08 2019-07-23 南京传奇生物科技有限公司 一种提高蛋白血清半衰期的组合物和方法
WO2018055535A2 (en) 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
US20210052721A1 (en) * 2018-03-16 2021-02-25 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof
CN109160942B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段502-518及其用途
WO2020154635A1 (en) * 2019-01-25 2020-07-30 Senti Biosciences, Inc. Fusion constructs for controlling protein function

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
AU7679491A (en) * 1990-04-04 1991-10-30 Protos, Inc. Hepatitis c virus protease inhibitors
US5747339A (en) * 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0468657A3 (en) 1990-07-09 1992-02-05 Tonen Corporation Non-a non b hepatitis-specific antigen and its use in hepatitus diagnosis
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
CA2055149A1 (en) 1990-11-08 1992-05-09 Hiroaki Okamoto Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides
JP3350729B2 (ja) * 1991-06-13 2002-11-25 デイド、ベーリング、インコーポレイテッド 非ａ非ｂ肝炎のためのイムノアッセイ
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
US5428145A (en) 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
CA2115926A1 (en) * 1991-08-21 1993-03-04 Stephen H. Dailey Hepatitis c assay utilizing recombinant antigens to ns1
RU2212899C2 (ru) * 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
ATE191792T1 (de) * 1991-09-16 2000-04-15 Abbott Lab Verfahren zur detektion von hepatitis c
WO1993015207A2 (en) 1992-02-04 1993-08-05 Viagene, Inc. Hepatitis therapeutics
BR9305435A (pt) * 1992-03-06 1994-12-27 Innogenetics Nv Processo para determinação de peptídeos correspondendo a epítopos imunologicamente importantes e seu uso em um processo para determinação de anticorpos ou peptídeos biotinilados correspondendo a epítopos imunologicamente importantes, processo para preparação dos mesmos e composições contendo os mesmos
CN1055701C (zh) * 1993-10-19 2000-08-23 味之素株式会社 能诱导对hiv免疫应答的肽及含有该肽的预防、治疗aids的药物
ATE290592T1 (de) * 1993-11-04 2005-03-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5543657A (en) * 1994-10-07 1996-08-06 International Business Machines Corporation Single layer leadframe design with groundplane capability

Also Published As

Publication number Publication date
ES2197170T3 (es) 2004-01-01
EP0992581B2 (de) 2011-05-25
DE69434295D1 (de) 2005-04-14
ATE236981T1 (de) 2003-04-15
WO1995012677A2 (en) 1995-05-11
WO1995012677A3 (en) 1995-07-27
US6555114B1 (en) 2003-04-29
EP0992581B1 (de) 2004-08-25
EP0725824B1 (de) 2003-04-09
PT725824E (pt) 2003-08-29
DK0992580T3 (da) 2005-07-11
JP2004194668A (ja) 2004-07-15
US6613333B1 (en) 2003-09-02
DK0725824T3 (da) 2003-08-11
DE69432475T2 (de) 2004-03-04
ES2239819T3 (es) 2005-10-01
EP0992580A2 (de) 2000-04-12
EP0992581A3 (de) 2001-03-07
AU698878B2 (en) 1998-11-12
EP0725824A1 (de) 1996-08-14
EP0992580A3 (de) 2000-08-09
ATE290592T1 (de) 2005-03-15
AU7993294A (en) 1995-05-23
CA2175692A1 (en) 1995-05-11
DE69433971T2 (de) 2005-09-08
EP0992580B1 (de) 2005-03-09
DE69432475D1 (de) 2003-05-15
ATE274578T1 (de) 2004-09-15
DE69434295T2 (de) 2006-02-16
EP0979867A3 (de) 2007-06-13
EP0979867A2 (de) 2000-02-16
US20040047877A1 (en) 2004-03-11
US6689368B1 (en) 2004-02-10
PT992580E (pt) 2005-07-29
JPH09504534A (ja) 1997-05-06
EP0992581A2 (de) 2000-04-12

Similar Documents

Publication Publication Date Title
DE69433971D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
FI941199A0 (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
ATA257190A (de) Virales polypeptid
DE68927025D1 (de) HIV-2-Virusvarianten
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
EP0523395A3 (de)
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
DE69534296D1 (de) Sektretierter E1/E2 Hepatitis C Virus-Komplex erhalten aus C-terminal verkürzten Polypeptiden E1 und E2
DE69132717T2 (de) Hepatitis-a-impfstoff
DK204588D0 (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
EP0637631A3 (de) Hoch effiziente Expression eines Polypeptids, das eine modifizierte preS1-Region des grossen Hepatitis B-Virus-Antigens enthält.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee